Boston Trust Walden Corp Buys 229,885 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Boston Trust Walden Corp significantly increased its stake in Jazz Pharmaceuticals, purchasing an additional 229,885 shares, bringing its total holdings to approximately 407,897 shares worth around $43.3 million.
• Despite reporting a loss of $8.25 EPS in its recent quarterly earnings, which missed analyst estimates, Jazz Pharmaceuticals' revenue increased by 2.1% year-over-year, totaling $1.05 billion.
• Most analysts maintain a positive outlook for Jazz Pharmaceuticals, with 14 ratings as "Buy", while the average price target is set at $178.93.

Boston Trust Walden Corp increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 129.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 407,897 shares of the specialty pharmaceutical company's stock after buying an additional 229,885 shares during the period. Boston Trust Walden Corp owned about 0.67% of Jazz Pharmaceuticals worth $43,286,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in JAZZ. Envestnet Portfolio Solutions Inc. lifted its position in shares of Jazz Pharmaceuticals by 170.9% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 11,834 shares of the specialty pharmaceutical company's stock worth $1,256,000 after purchasing an additional 7,465 shares during the period. Ellis Investment Partners LLC increased its stake in Jazz Pharmaceuticals by 13.2% during the 2nd quarter. Ellis Investment Partners LLC now owns 6,045 shares of the specialty pharmaceutical company's stock valued at $641,000 after purchasing an additional 707 shares in the last quarter. CWM LLC increased its stake in Jazz Pharmaceuticals by 197.1% during the 2nd quarter. CWM LLC now owns 3,740 shares of the specialty pharmaceutical company's stock valued at $397,000 after purchasing an additional 2,481 shares in the last quarter. Blue Trust Inc. increased its stake in Jazz Pharmaceuticals by 6.8% during the 2nd quarter. Blue Trust Inc. now owns 3,152 shares of the specialty pharmaceutical company's stock valued at $334,000 after purchasing an additional 200 shares in the last quarter. Finally, Callan Family Office LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth $619,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $133.81 on Wednesday. The firm has a market cap of $8.12 billion, a PE ratio of -19.88, a price-to-earnings-growth ratio of 8.30 and a beta of 0.28. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The business has a 50 day moving average price of $126.67 and a 200-day moving average price of $115.79.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same period in the previous year, the business earned $5.30 EPS. The business's revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on JAZZ shares. Weiss Ratings reiterated a "sell (d)" rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th. The Goldman Sachs Group upped their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research report on Friday, August 29th. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Finally, Royal Bank Of Canada upped their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $178.93.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 11,500 shares of company stock valued at $1,525,280 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.